SIOUX FALLS, S.D., March 09, 2017 -- Raven Industries, Inc. (NASDAQ:RAVN) announced today that its board of directors has approved a regular quarterly cash dividend of 13 cents per share. The dividend is payable April 28, 2017, to shareholders of record on April 17, 2017.
About Raven Industries, Inc.:
Raven Industries (NASDAQ:RAVN) is dedicated to providing innovative, high-value products and solutions that solve great challenges throughout the world. Raven is a leader in precision agriculture, high-performance specialty films, and lighter-than-air technologies. Since 1956, Raven has designed, produced, and delivered exceptional solutions, earning the company a reputation for innovation, product quality, high performance, and unmatched service. For more information, visit http://ravenind.com.
Contact Information: Bo Larsen Investor Relations Manager Raven Industries, Inc. +1 (605) 336-2750


Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



